Buscar
Regeneron Pharmaceuticals Inc
REGNAñadir a la lista de seguimiento
618.030USD
+5.530+0.90%
Cierre 06/23, 16:00（ET）Cotizaciones retrasadas 15 min
64.79BCap. mercado
14.55P/E TTM
Más Datos de Regeneron Pharmaceuticals Inc Compañía
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Información de Regeneron Pharmaceuticals Inc
Símbolo de cotizaciónREGN
Nombre de la empresaRegeneron Pharmaceuticals Inc
Fecha de salida a bolsaApr 02, 1991
Director ejecutivoSchleifer (Leonard S)
Número de empleados15106
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 02
Dirección777 Old Saw Mill River Road
CiudadTARRYTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10591
Teléfono17813705000
Sitio Webhttps://www.regeneron.com/
Símbolo de cotizaciónREGN
Fecha de salida a bolsaApr 02, 1991
Director ejecutivoSchleifer (Leonard S)
Ejecutivos de Regeneron Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.80K
+0.07%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.42K
-0.57%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.49K
+0.82%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.78K
+0.04%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Regeneron Pharmaceuticals Inc?
Los cinco principales accionistas de Regeneron Pharmaceuticals Inc son: Dr. George D. Yancopoulos, M.D., Ph.D
¿Cuántas instituciones poseen acciones de Regeneron Pharmaceuticals Inc (REGN)?
A fecha de 2026Q1, 2806 instituciones poseen acciones de Regeneron Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 94.67M, lo que representa el 91.89% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1673066.00.
¿Cuál es la mayor fuente de ganancias de Regeneron Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial Sanofi generó la ganancia más alta para Regeneron Pharmaceuticals Inc, ascendiendo a 5.88B y representando el 41.02% de la ganancia total.
